PD-L1 inhibitor in combination with tumor-derived mHSP/peptide vaccine induced the section of IFNγ, TNFα, IL-10 and IL-2 on day 14th whereas on day 28th combinational treatment led to decrease production of IFNγ, IL-2 and IL-10 (170). Here, IL2 is linked to neoplasm.